Signal #135229 · SEC 8-K

$SMMT SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $SMMT filing catalyst

Why did $SMMT trigger an AI stock catalyst alert?

$SMMT triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.0/10). Headline: Summit Therapeutics Q3 Net Loss Narrows to $208.4M (-$0.26/sh), Advances Ivonescimab Trials. Key points: - Q3 GAAP net loss narrowed to $208.4 million or $(0.26) per share compared to $(231.8) million or $(0.31) per share in Q3 prior year. - GAAP operating expenses decreased to $214.6 million from $234.2 million, driven by lower G&A costs. - Clinical trials for Ivonescimab continue expansion into bladder and kidney cancer programs.

How did $SMMT stock react after the SEC filing?

After the SEC 8-K for $SMMT, observed market reaction: T0 price $16.17. Past moves do not guarantee future results.

Where can I get real-time $SMMT SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $SMMT via Telegram and the VIP Web Terminal from €10/month.

$SMMT

$SMMT – Summit Therapeutics Q3 Net Loss Narrows to $208.4M (-$0.26/sh), Advances Ivonescimab Trials

Summit Therapeutics Inc.

2026-11-04 00:00:00 UTC · SEC 8-K · All $SMMT

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+3.0 / 10)

Q3 GAAP net loss narrowed to $208.4 million or $(0.26) per share compared to $(231.8) million or $(0.31) per share in Q3 prior year.
GAAP operating expenses decreased to $214.6 million from $234.2 million, driven by lower G&A costs.
Clinical trials for Ivonescimab continue expansion into bladder and kidney cancer programs.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →